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Mutations in the X-linked MECP2 gene are associated with a wide spectrum of 
neurological disorders, of which Rett syndrome represents the first identified and surely 
the best characterize. Although MeCP2 has been originally described as an epigenetic 
transcriptional repressor, it is now evident that it actually behaves as a multifunctional 
protein. Indeed, in addition to its role in inhibiting gene transcription, it can serve as a 
chromatin remodeling factor, a transcriptional activator and a modulator of mRNA 
splicing (1). As consequence of its involvement in all such molecular processes, lack 
or mutations of MECP2 generate a plethora of symptoms, as those displayed in Rett 
syndrome. Importantly, several mouse models of Mecp2 recapitulate many of the 
typical RTT phenotypes, thus helping in the characterization of the molecular, 
functional and behavioral features of the pathology. Remarkably, they also served to 
establish that Rett syndrome is a potentially reversible neurological condition, thus 
encouraging many preclinical studies that in some cases advanced to clinical trials in 
patients (2). However, both clinical and preclinical studies have clearly demonstrated 
to suffer from the lack of measurable outcomes that could be used to longitudinally 
describe the progression of both the symptoms and the pathological mechanisms 
occurring in Rett syndrome. Based on these measurements, which are here defined as 
“biomarkers”, researchers could easily test the efficacy of a treatment in ameliorating 
or stalling the progression of the disorder. To date, however, to the best of our 
knowledge, such biomarkers are unavailable to the Rett syndrome scientific community 
and a spatial and temporal map of the genesis and occurrence of phenotypes is still 
lacking.  
Currently, the approaches proposed in the field of Mecp2 studies are mostly based on 
assessments that produce only steady state data taken at a singular and defined time 
point. This is clearly incompatible with longitudinal studies, highlighting the urgency 
of identifying biomarkers of the disease progression. Ideally, measurable outcomes 
should satisfy the following criteria: i) they should be detectable both in animal models 
and humans, thus ensuring the clinical relevance of the analysis; ii) they should be 
measurable at different time points in the same subject; iii) they should provide 
quantitative and not only qualitative data. By considering a measurable outcome that 
possess all these features, researchers could reach a more detailed comprehension of 
the genesis of RTT pathological mechanisms and their progression in time, thus 
contributing to the development of sound rescue strategies. This obviously represents 
the roadmap to obtain efficient therapeutic approaches for Rett syndrome. 
In light of these considerations, the review recently proposed by Mueller on disturbed 
redox homeostasis and oxidative stress in Rett syndrome, and published in the Special 
Issue on Regression in Developmental Disorders, fits well with the current needs of 
Rett research. In fact, the author not only comprehensively reviews the state of 
knowledge on redox imbalance and oxidative stress in Rett syndrome, but also suggests 
a novel genetic tool to analyze redox alterations along the disease progression. We find 
this an interesting and promising approach for the study of RTT.  
Alterations in redox have been reported both in patients and in animal models (3,4), 
implying the possible importance of such imbalance in the pathogenesis of RTT. 
Further, although it is not currently possible to clearly establish a molecular mechanism 
through which Mecp2 deficiency generates redox imbalance, data from Mecp2 re-
expression experiments support a link between them (3). This association could depend 
on either mitochondrial dysfunction or impaired detoxification or both. Further, 
preclinical and clinical reports showed the benefic impact of interventions aimed at 
balancing redox impairments. However, we still have to understand when oxidative 
insults appear and whether different tissues are differently susceptible. Once again, this 
stresses the importance of longitudinal studies for the comprehension of the timing 
through which redox imbalance is associated with the pathology.  
So far measurements of redox were based on histological or biochemical assessments; 
however; the review by Mueller highlights the development of genetic tools, already 
used in in vitro experiments (5) that now allow longitudinal studies in mice. These 
systems exploit transgenic mice expressing optical sensors of redox, such as a redox 
sensitive fluorescent protein (roGFP). The possibility of using different promoters 
driving the expression of the transgene enables to image redox changes selectively 
within specific cell compartments, cells types and tissues. Redox can be quantitatively 
measured in a specific tissue of the same animal along the disease progression. Indeed, 
an interest aspect of redox-based impairments highlighted in the review is the cyclic 
succession of three temporal stages: redox alterations, followed by oxidant burden that 
eventually leads to oxidative tissue damage. Together these stages set in motion a 
vicious cycle, in which oxidative tissue damages enhance the production of free oxygen 
radicals that maintain and amplify the damage. It is intriguing to imagine that initial 
redox alterations arise during the so-called pre-symptomatic phase of the disorder 
characterized by subclinical manifestations, while oxidative stress and tissue damage 
concur to the overt phase of the pathology. If this is the case, the use of these animals 
could shed new light on the molecular basis of the pre-symptomatic and symptomatic 
phase of the pathology. Moreover, these probes could potentially enable to measure the 
benefits of any therapeutic treatment, including those that not necessarily directly 
modulate the redox status. Indeed, we foresee that the use of conditional Mecp2 animals 
in combination with redox sensors could generate novel tools to clarify how Mecp2 
deficiency impacts redox balance in specific brain areas as secondary affect. Similarly, 
this tool would offer a new measurable outcome to test the rescue potential of drugs 
targeting the effects of conditional Mecp2 ablation, an undeniable advantage for the 
purpose of preclinical studies. 
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